Formycon AG

General information
Formycon AG
Fraunhoferstra├če 15
82152 Martinsried/Planegg, Bavaria

Contact person: Stefan Glombitza, Chief Executive Officer
Company main phone: +49 (89) 864667100
Company main fax:  +49 (89) 864667110
Year founded:1999
Source of foundation:Independent foundation
No. of employees: Worldwide:  238
Corporate description / mission:
Formycon is a developer of biopharmaceutical medicines, especially biosimilars. The company is focused on the treatments in ophthalmology, immunology and on other key chronic diseases. The company's biosimilar candidates are FYB201, FYB202, FYB203 etc.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 2012
Remarks on ownership / listings
In 1999, founded the Scil Group.
In 2012, changed the name to Formycon AG
  • Pharma (fully integrated)
  • Anti-infectives
  • Biosimilars
  • Immunotherapy
Primary therapeutic areas:
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Diseases of the eye / ophthalmology
  • Infectious and parasitic diseases / infectiology / parasitology
  • Neoplasms / cancer / oncology
  • Skin and subcutaneous tissue / dermatology
  • Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Business model:
  • R&D
Customer segments:
  • Hospitals
  • Large biotech & big pharma
  • Small biotech
Summary Products / Services / Technologies
Number of Biotech Products
Phase III:2
On the market:3
Description of products:
FYB207 etc.
Financing details
Fiscal year (end of) 2023
Revenues:USD 84.07M
R&D expenses:USD 9.91M
Net earnings:USD 82.01M
Cash:USD 29.25M
Total liabilities:USD 419.40M
No. of shares:17'656'900
Market cap. / valuation:USD 822.31M